- TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
- TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
- TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
- TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
- TriSalus Reports Q1 2024 Financial Results and Business Update
- TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
- TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
- TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
More ▼
Key statistics
As of last trade, TriSalus Life Sciences Inc (TLSI:NMQ) traded at 5.00, 50.60% above the 52 week low of 3.32 set on Nov 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.00 |
---|---|
High | 5.00 |
Low | 4.84 |
Bid | 5.00 |
Offer | 5.18 |
Previous close | 5.06 |
Average volume | 40.52k |
---|---|
Shares outstanding | 27.16m |
Free float | 10.52m |
P/E (TTM) | -- |
Market cap | 137.43m USD |
EPS (TTM) | -2.09 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 15:03 BST.
More ▼